The AI Secret Nobody Sees Coming

Keith Kohl

Written By Keith Kohl

Updated May 15, 2024

You probably have never heard of Friedrich Wilhelm Adam Sertürner. 

Don’t beat yourself up too bad if the name doesn’t ring a bell. Because very few people have heard of this name. Yet Sertürner holds an interesting place in the history of medicine. 

Sertürner was a pharmacist's assistant living in the south of lower Saxony in Germany at the beginning of the 19th century. Throughout his years as an assistant, and later as a pharmacist, he worked on a new method of isolating morphine from opium. 

You could hardly call his early work a success. Not only was he using an impure alcoholic extract of opium, but he was also testing on stray dogs, mice, and on occasion… himself. 

In fact, it took more than 11 years before he was able to extract crystals of pure morphine through precipitation. 

This was the first notable moment in human drug discovery. 

Historically, scientists would either identify an active ingredient from a traditional remedy, or through sheer blind luck.

Perhaps the most famous example that comes to mind took place in 1928. After coming back from vacation, Alexander Fleming  discovered mold growing on his petri dish in his lab. 

eac image 1

Interestingly, the mold was preventing the staphylococcus bacteria from growing around it, and thus penicillin was discovered. 

What you may not realize, however, is that Fleming’s discovery of penicillin was shrugged off by his peers at the time. It was written off as a freak occurrence.

Because no matter how much they tried, they couldn’t purify penicillin, and thus was regarded as more of a curiosity by the scientific community. 

It took another ten years before two scientists, Ernst Chain and Howard Florey, formed a team to systematically produce a pure form of penicillin. 

Then, it took another three years after that before the “Penicillin Project” became a success. 

More than 80 years later, the drug discovery process is still plagued by two huge obstacles: Time and money.

But that’s all about to change…

Despite all the advancements we’ve made in the past century, you would be shocked at the numbers. 

I know it’s easy to denigrate Big Pharma in today’s society. Like Big Oil, they’re an easy scapegoat; sometimes that blame is deserved, but sometimes it's not. 

From discovery to approval, it can take a company up to 20 years and cost tens of billions of dollars to bring a new drug to market. 

In 2019 alone, the pharmaceutical industry spent $83 billion on research and development. 

If that sounds bleak, just remember that 90% of potential drug candidates that make it to clinical trials fail to make it through the approval process. 

But that entire process is about to be turned upside down due to this technology. 

And I know all of my readers have come across this technology over the last two years: Artificial Intelligence.

AI-assisted drug discovery may sound like something out of science fiction, but it’s far closer to reality than you might first think. We’re far beyond chatting on OpenAI, Google’s Bard, or creating some fascinating AI images using Midjourney. 

Through the use of certain AI systems, scientists can greatly increase target identification during the drug discovery phase, run simulations that would reduce the need for physical testing, utilize its algorithms to prioritize potential molecules and even generate synthesis pathways for manufacturing these compounds. 

This is beyond game-changing. 

Thing is, this technology is still in its infancy. That means there are only a few players in the AI drug discovery race. 

Once this is successful, it’ll be one of the most groundbreaking opportunities in the biotech sector.  

I strongly recommend you take just a few minutes out of your day and check out all the details in this investment presentation. 

The next step is up to you

Until next time,

Keith Kohl Signature

Keith Kohl

follow basicCheck us out on YouTube!

A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.

For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.

Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.

Angel Publishing Investor Club Discord - Chat Now

Keith Kohl Premium



Hydrogen Fuel Cells: The Downfall of Tesla?

Lithium has been the front-runner in the battery technology market for years, but that is all coming to an end. Elon Musk is against them, but Jeff Bezos is investing heavily in them. Hydrogen Fuel Cells will turn the battery market upside down and we've discovered a tiny company that is going to make it happen...

Sign up to receive your free report. After signing up, you'll begin receiving the Energy and Capital e-letter daily.